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Novelty statement: This study sought to examine cerebrovascular reactivity in 
subjects with impaired glucose tolerance (IGT) and type 2 diabetes using magnetic 
resonance phase contrast angiography. We demonstrated impaired cerebrovascular 
reactivity in both cohorts in comparison with healthy volunteers. This is the first 
report in IGT of impaired cerebrovascular reactivity, which has previously been 
linked to increased risk of stroke. Furthermore, our report highlights the presence of 
significant cerebrovascular disease in this cohort of asymptomatic individuals. 
OBJECTIVE  
The aims of this study were 1) to examine cerebrovascular autoregulation in subjects 
with impaired glucose tolerance (IGT) and type 2 diabetes (T2DM) and 2) to clarify is 
cardiovascular autonomic nerve function is associated with abnormal 
cerebrovascular autoregulation. 
RESEARCH DESIGN AND METHODS 46 subjects were recruited [12=IGT, 
17=T2DM and 17=Healthy Volunteers (HV)]. Arterial blood flow (fICA) was assessed 
within the internal carotid artery (ICA) at baseline and 20 minutes after intravenous 
pharmacological stress (1g acetazolamide), using quantitative magnetic resonance 
phase-contrast angiography. ICA vascular reactivity [VRICA(%)] and pulsatility index 
(PI) was determined. All subjects underwent baroreceptor reflex sensitivity 
assessment. 
RESULTS Subjects with IGT and T2DM had significantly lower VRICA [40.2%(19.8)  
and 41.5%(18.7)], respectively] compared with HV [57.0%(14.2); ANOVA p=0.02]. 
There was no significant difference in VRICA between T2DM and IGT groups 
(p=0.84). There was a significant positive correlation between baroreceptor reflex 
sensitivity (LF:HF) with CRV (U= 0.47, p=0.04). and PI (U = 0.46, p=0.04). 
CONCLUSIONS We have demonstrated significant cerebrovascular haemodynamic 
abnormalities in subjects with T2DM and IGT. This was associated with greater 
sympathovagal imbalance. This may provide an important mechanistic explanation 
for increased risk of cerebrovascular disease in diabetes. It also highlights that these 
abnormalities may already be present in prediabetes. 
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Type 2 diabetes mellitus (T2DM) and impaired glucose tolerance increases the risk 
of ischaemic stoke (1-4). Although, epidemiological studies have linked increased 
duration of diabetes and poor metabolic control to stroke risk, paradoxically, large 
randomised studies have failed conclusively to show that intensively lowering 
glucose reduces cardiovascular event rates (including stroke) (5,6). Hence, the 
cause of an increased stroke risk in diabetes remains unclear. 
Cerebral blood flow is carefully regulated to exceed the metabolic demands of 
the brain (7). Metabolic coupling mechanisms ensure that blood flow is increased in 
regions that are metabolically active (8) and autoregulation maintains blood flow 
during changes in perfusion pressure (9). Abnormal cerebrovascular autoregulation 
is associated with an increased risk of stroke as it impairs the ability to compensate 
in response to a fall in perfusion pressure (10-14). This has been widely reported in 
patients with diabetes as impaired cerebrovascular reactivity to a variety of 
haemodynamic challenges [e.g. hypercapnia, acetazolamide (ACZ) and blood 
pressure changes (15-18)]. Abnormal cerebrovascular autoregulation has also been 
demonstrated in diabetic subjects with severe cardiac autonomic neuropathy (19).  
Given the increased risk of stroke in prediabetes, we evaluated whether IGT is 
associated with abnormal cerebrovascular autoregulation by examining vascular 
reactivity of the internal carotid artery in response to pharmacological vasodilatory 
challenge using quantitative magnetic resonance (MR) angiography. We also 
examined the relationship between cerebrovascular autoregulation and 
cardiovascular autonomic function. Therefore, the aims of this study were 1) to 
examine the cerebrovascular autoregulation in patients with IGT and 2) to examine 
the relationship between cerebrovascular autoregulation and autonomic function 
assessed by baroreceptor gain using established spectral techniques.  
RESEARCH DESIGN AND METHODS 
Forty six subjects [IGT, n=12; T2DM, n=17 and 17 healthy volunteers (HV)] were 
studied. Impaired glucose tolerance was defined as previously described (20). We 
excluded any patients with uncontrolled diabetes, a history of cerebrovascular 
disease or the presence of MRI findings compatible with stroke/ischaemic change or 
had evidence of significant carotid artery stenosis; known symptomatic heart disease 
that can alter cardiac output; peripheral vascular disease; neurological diseases; 
uncontrolled hypertension; insulin treatment; renal impairment; current smokers or 
ex-smokers (<12months) and medications (e.g. E-blockers) or illnesses (e.g. 
anaemia or polycythemia) that can alter cerebrovascular reactivity, central 
chemosensitivity or cerebral blood flow. Standard MR exclusion criteria were 
adopted. If present, the degree of diabetic retinopathy (DR) was quantified using 
digital retinal photography from the annual eye screening database. All subjects 
gave written, informed consent before participation in the study, which had prior 
approval by the Regional Ethics Committee. 
Baroreceptor Reflex Sensitivity 
Spectral measurements of baroreflex gain were performed in the morning, in the 
supine position using the Portapres Device (Finapres Medical Systems, Amsterdam, 
The Netherlands). Portapres self-adjustment was performed for 15 minutes to 
ensure patient and signal stabilisation. Following self-adjustment, an 8-min recording 
of ECG and blood pressure signals was performed.  
Cardiac and systolic arterial pressure time series were computed using dedicated 
software provided by the manufacturer. Computation of spectral components in the 
low frequency (LF) band (from 0.04 to 0.15 Hz) and in the high frequency (HF) band 
(from 0.15 to 0.45 Hz) was performed. The square root of the ratio between cardiac 
and systolic arterial pressure spectral components in both bands provided the alpha-
LF and alpha-HF indices respectively. The ratio between LF and HF was also 
calculated. 
Magnetic Resonance Imaging Protocol 
All data were acquired at 3.0 T (Achieva3.0T, Philips Healthcare, Best, Holland). 
Standard T2-weighted and Fluid Attenuated Inversion Recovery (FLAIR) images 
were acquired in the axial plane using 2-dimensional, fast-spin-echo techniques. 
Finger-prick blood glucose testing was performed during the MR imaging session to 
ensure it remained within 4-12 mmol/l. Magnetic Resonance Angiography (MRA): 
Standard time-of-flight MRA was performed over the right carotid artery bifurcation to 
aid subsequent angiographic slice placement. Quantitative phase-contrast 
angiography (PCA) data (TE=4.4ms; TR=8.0ms; FA=10O; velocity encoding factor 
[VENC]=120cm/s) were acquired from a single 4mm thick slice with in-plane pixel 
dimensions of 1.72 x 1.59 cm2 . The PCA-acquisition slice was placed approximately 
3cm distal to the carotid bifurcation, perpendicular to the axis of flow within the right 
ICA, in order to maximise the extent of laminar flow-detection. Centrally acquired 
vector ECG data were used to retrospectively gate 40 time points within the cardiac 
cycle allowing blood flow to be assessed during each phase of the cardiac cycle. 
Following initial PCA, 1g ACZ (Diamox Sodium parenteral, Wyeth laboratories, 
Maidenhead) was administered intravenously over 10 minutes through a cannulated 
antecubital vein whilst the subject remained in the scanner. An identical PCA 
acquisition was repeated 20 minutes post-ACZ administration.  
Quantitative velocity and flow - encoded information were extracted from the MR-
PCA datasets obtained from each subject via user-defined region of interest, post-
acquisition, proprietary processing software (Q-flow, Philips Healthcare, Best, 
Holland). Regions of interest were drawn on the resultant phase contrast images 
corresponding to the time-point of maximum arterial flow. The following established 
markers of ICA haemodynamics and autoregulation were used as outcome variables 
(21,22):  
1. Arterial blood flow (fICA, ml/s), refers to the average volume of blood per unit 
time 
2. ICA vascular reactivity (VRICA, %) = [(fICAPOST - fICAPRE) / fICAPRE] x 100 
Where fICAPRE = mean blood flow through the ICA pre ACZ administration and 
fICAPOST = mean blood flow through the ICA flow post ACZ administration.  
3. Pulsatility index (PI) = [fICAMAX- fICAMIN] / fICAMEAN 
Where fICAMAX = maximum flow during the cardiac cycle, fICAMIN = minimum flow 
during the cardiac cycle and fICAMEAN = mean flow throughout the cardiac cycle. 
Severely impaired VRICA was defined as <10% increase as described previously 
(23).  
Statistical Analysis 
All analyses were performed using standard statistical techniques (SPSS 21.0, IBM 
Inc.). Baseline characteristics were described as means and standard deviation for 
normally distributed variables. The appropriate tests for normality were conducted to 
guide subsequent analysis. Demographic and outcome variables were compared 
between groups using one-ZD\$129$ZLWK)LVKHU¶VSRVW-hoc test. Paired sample t-
tests were used to compare mean fICA determined pre- and post-ACZ. Finally, 
ANCOVA (age as covariate) was used to examine mean PI and RI of HV, IGT and 
T2DM subject groups divided into those with (T2DM-DR; n=7) and without (T2DM-
NoDR; n=7) retinopathy. The linear association between the baroreceptor sensitivity 
and MR measures of ICA haemodynamics and autoregulation was assessed by 
Spearman correlation analysis in IGT and T2DM subgroups. 
RESULTS 
There were no significant group differences in age or gender distribution (Table 1). 
IGT and T2DM subjects had significantly greater body mass index and waist 
circumference compared with HV (Table 1). Mean HbA1c in the T2DM cohort was 
9.5(1.9)% (75.0mmol/mol). There were no significant differences in pre-ACZ mean 
fICA between groups [ml/s; HV (4.36(0.7), IGT 4.88(0.9), T2DM 4.34(1.0); ANOVA 
p=0.19; Figure 1B]. In all groups there was a significant increase in subject fICA post-
ACZ [ml/s; HV (6.85(1.2), IGT 6.75(1.0), T2DM 5.37(2.4); p<0.001; Figure 1B].  
VRICA (%) was significantly greater in HV [57.0(14.2)] compared to IGT 
[40.2(19.8)] and T2DM [41.5(18.7), ANOVA p=0.02; Figure 1C, post-hoc tests Table 
1]. After correction for BMI and waist circumference mean VRICA remained 
significantly greater in HV (ANCOVA p=0.04). There was no significant difference in 
VRICA (%) between IGT and T2DM subjects (p=0.84). One subject each from T2DM 
(5.9%) and IGT (8.3%) cohorts had severely impaired VRICA. Subjects with T2DM 
[1.14(0.3)] had the highest mean PI compared to HV [1.01(0.2)] and IGT [1.04(0.2); 
ANOVA p=0.24, Table 1]. T2DM-DR subjects were older compared to T2DM-NoDR 
subjects [years, 60.6(15.8) vs. 51.0(9.5)]. After correction for age, mean PI were 
significantly higher in T2DM-DR when compared with the T2DM-NoDR subgroup, 
IGT and HV groups [ANCOVA, p=0.02; Figure 1D, post-hoc tests Table 1].  
There was a significant positive correlation between baroreceptor reflex sensitivity 
measure LF:HF with CRV (U= 0.47, p=0.04). and PI (U = 0.46, p=0.04). Only HF and 
not LF demonstrated a significant correlation with CRV (U =-0.53, p=0.02) and PI 
(U=-0.46, p=0.04).   
DISCUSSION 
In this preliminary study, we have demonstrated impaired cerebrovascular 
reactivity not only in T2DM subjects but also in those with IGT. This suggests poor 
cerebral blood flow reserve and abnormal cerebral autoregulation. Therefore, during 
an acute ischaemic insult collateral vessels may be unable to re-perfuse the 
ischaemic penumbra to maintain its viability. To our knowledge, this is the first report 
of impaired cerebrovascular reactivity in subjects with IGT. Endothelial cell mediated 
vasodilatation is thought to play an important role in the intracerebral response to 
ACZ (24) and could be responsible for impaired cerebrovascular reactivity in IGT and 
T2DM.  
The Gosling PI is a measure of vascular resistance originally performed on 
the brachial artery in humans (25). It has since been frequently used in studies to 
reflect increase in cerebrovascular resistance (26,27). In our study, ICA PI was 
significantly greater in T2DM subjects with microvascular disease (DR). This is 
consistent with the literature and thought to reflect greater cerebrovascular 
microangiopathy. Thus, our finding of impaired CVR but not pulsatility in IGT 
subjects probably reflects a relatively greater degree of endothelial vasodilatory 
dysfunctional than a microangiopathic pathology. This would suggest it could be 
amenable to pharmacological treatment (e.g. low-dose aspirin is known to have 
vasoactive properties that may be through a cyclooxygenase independent pathway) 
or aggressive risk factor modification.  
Autonomic nervous system alterations may also play a role in the 
cerebrovascular haemodynamic differences demonstrated. We found that changes 
in sympatho-vagal balance (LF:HF ratio) were moderately associated with CVR and 
PI. This appears to be driven by the variance in HF but not LF. Efferent vagal activity 
is a major contributor to the HF component of spectral analysis of baroreceptor gain 
as seen in clinical and experimental observations. Interpretation of the LF 
component is less clear, some consider it a marker of sympathetic modulation and 
by others as a parameter that includes both sympathetic and vagal influences. The 
LF:HF ratio assesses the controlled and balanced activity of the two branches of the 
autonomic nervous system.  Although the results of this study are consistent with the 
hypothesis of autonomic dysfunction being involved in abnormal cerebrovascular 
reactivity, the cross-sectional design limits interpretation of causality. Further work is 
necessary to examine if abnormal sympatho-vagal balance results in worse 
outcomes post stroke and if pharmacological treatments can ameliorate this. 
A number of different techniques have been used to assess CVR. The 
commonest method is the use of transcranial Doppler ultrasound measurement of 
middle cerebral artery velocity. Using this method several investigators have 
demonstrated reduced CVR in patients with type 1 and 2 diabetes (28-29). Impaired 
CVR was also demonstrated in diabetic subjects with established microvascular 
complications [retinopathy (30) and nephropathy (31)]. Transcranial Doppler 
ultrasound is a non-invasive, inexpensive technique that only measures blood 
velocity. Its main limitation is it assumes that changes in velocity are directly 
proportional to changes in blood flow and therefore the arterial diameter remains 
constant (32). Consequently it overestimates blood flow (33). There is also 
significant inter-operator variability influencing its reliability and 5-15% of patients 
cannot undergo transcranial Doppler of the middle cerebral artery as there is an 
insufficient temporal bone acoustic window (34). Magnetic resonance PCA provides 
a reliable and reproducible method of quantifying blood flow and can be used to 
investigate arterial blood input to the brain, within the carotid and vertebral arteries. It 
also measures both blood flow and velocity and does not rely on the assumption of 
arterial diameter being constant. The disadvantages are that it is costly, requires 
longer imaging times and there are more contraindications to MRI scanning 
compared to ultrasound techniques. A recent study reported impaired vascular 
reactivity in subjects with impaired glucose tolerance and T2DM by measuring 
changes in retinal vessel diameter to flickering light (35). However, their exclusion of 
subjects with retinopathy, limits the widespread application of this method to the 
population of diabetes as a whole. 
The main limitation of the current study is the relative small sample size. 
However, our goal was to assess whether abnormalities in cerebrovascular 
autoregulation are present in IGT. The data presented here at least preliminarily 
support this view. There are also limitations associated with the use of ACZ. 
Although it is the most applied stimulus for cerebral vasodilatation in a clinical 
setting, there is a degree of individual variability in response to a standardised dose 
of ACZ. While a single 1g dose of ACZ is often used, this does not necessarily 
produce a maximum CBF if it is less than 15mg/kg (36). Even with an effective 
supramaximal ACZ dose, CBF continues to respond to ventilation induced changes 
in PCO2 and to changes in blood pressure (37), both are confounding factors that 
can affect CBF. Future studies should consider using CO2 inhalation as an 
alternative stimulus as its administration is non-invasive and easily terminated (38).  
Such studies may lead to identification of objective haemodynamic correlates of 
cerebrovascular disease that may serve as surrogate biological endpoints to 
evaluate interventions designed to prevent vascular complications of diabetes.  
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